This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)

This study is currently recruiting participants.
See Contacts and Locations
Verified March 2017 by Providence Health & Services
Sponsor:
Collaborator:
IRX Therapeutics
Information provided by (Responsible Party):
Providence Health & Services
ClinicalTrials.gov Identifier:
NCT02950259
First received: October 28, 2016
Last updated: March 1, 2017
Last verified: March 2017
  Purpose
The goal of this study is assess the safety and tolerability of the IRX-2 regimen in patients with early stage breast cancer (ESBC).

Condition Intervention Phase
Breast Neoplasm Breast Neoplasm, Male Drug: Cyclophosphamide Drug: Indomethacin Drug: Omeprazole Dietary Supplement: Multivitamin Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase Ib Study to Assess the Safety, Tolerability and Immunologic Activity of Preoperative IRX 2 In Early Stage Breast Cancer

Resource links provided by NLM:


Further study details as provided by Providence Health & Services:

Primary Outcome Measures:
  • Surgical Delays [ Time Frame: Day 1 to Day 26 ]
    Number of surgeries delayed due to adverse events from the IRX-2 regimen


Secondary Outcome Measures:
  • Tumor Infiltrating Lymphocytes [ Time Frame: Day 26 ]
    Change in tumor infiltrating lymphocyte (TIL) score as measured by H&E TIL count according to Salgado criteria from pre-surgical biopsy to resected tumor specimen


Other Outcome Measures:
  • Characterization of peripheral lymphocytes [ Time Frame: Day 1 to Day 26 ]
    Number of peripheral lymphocytes including activated T-cells, T-regulatory cells, natural killer (NK) cells, and myeloid cells

  • TIL phenotype [ Time Frame: Day 1 to 26 ]
    Changes in abundance of T-regulatory cells, activated T-cells, myeloid lineages and dendritic cells

  • Intratumoral T-cell response [ Time Frame: Day 1-26 ]
    change in T-cell clonal responses by T-cell receptor DNA deep sequencing

  • Intratumoral Immune Response [ Time Frame: Day 1-26 ]
    Characterization of intratumoral immune responses by RNA expression using the Nanostring PanCancer Immune panel and/or Prosigna tumor recurrence score


Estimated Enrollment: 20
Actual Study Start Date: February 9, 2017
Estimated Study Completion Date: November 2018
Estimated Primary Completion Date: April 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: IRX-2 Regimen
All enrolled subjects will receive a single dose of cyclophosphamide (300 mg/m2) by IV infusion on Day 1. Also starting on Day 1 and continuing until Day 21, subjects will take daily oral indomethacin (25 mg three times each day), daily oral omeprazole (one tablet) and daily oral multivitamin containing 15-30 mg of zinc. On any 10 consecutive day period between Days 4-17, patients will receive two 1 mL subcutaneous periareolar injections of IRX-2.
Drug: Cyclophosphamide
One dose of cyclophosphamide 300 mg/m2 IV infusion
Other Name: Cytoxan
Drug: Indomethacin
Indomethacin 25 mg three times a day for 21 days
Other Name: Indocin
Drug: Omeprazole
One tablet of omeprazole daily for 21 days
Other Name: Prilosec
Dietary Supplement: Multivitamin
Daily multivitamin containing 15-30 mg of zinc for 21 days.
Other Name: Vitamin

Detailed Description:

This will be a Phase Ib study conducted to determine the safety and tolerability of an IRX-2 regimen in ESBC, to be administered pre-operatively before standard-of-care surgical resection and following standard-of-care diagnostic biopsy.

Eligible subjects will have early stage breast cancer of any receptor subtype, for which standard-of-care surgical resection is planned. To be eligible, a minimum of 1 core of tumor-bearing biopsy material must be available for research analysis.

The IRX-2 regimen will be administered in all enrolled subjects. IRX 2 will be administered by subcutaneous injection into the periareolar skin of the affected breast.

  Eligibility

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Invasive breast cancer of any receptor subtype diagnosed by core-needle biopsy
  • To undergo surgical resection with curative intent by partial mastectomy (lumpectomy) or mastectomy
  • Tumor >5 mm in maximum diameter by ultrasound or mammography. (Subjects with smaller tumors may be included at the discretion of the Principal Investigator.)
  • Willing and able to provide written informed consent, including consent for use of available tissue and required blood draws for research purposes
  • Availability of at least one tumor-bearing core specimen from the breast cancer diagnostic biopsy
  • Karnofsky Performance status (KPS) 70% or greater.
  • Female or male ≥18 years of age on day of signing informed consent.
  • Adequate organ function as defined by protocol specified lab results

Exclusion Criteria:

  • Prior neoadjuvant systemic therapy is planned
  • Prior surgery, radiotherapy or chemotherapy for this cancer (other than core-needle biopsy)
  • Received an investigational agent within 4 weeks of the first dose of treatment.
  • Diagnosis of immunodeficiency or has received more than replacement doses of corticosteroids any other immunosuppressive therapy within 4 weeks of the first dose of treatment
  • Hypersensitivity to IRX 2, cyclophosphamide, indomethacin, aspirin or ciprofloxacin.
  • Chronic anticoagulation, not including aspirin, but including heparins, warfarin, oral anticoagulants or other platelet function inhibitors, that cannot, in the documented opinion of the investigator, safely be interrupted from at least 2 days prior to the initiation of the study regimen until after surgical resection of the tumor.
  • Another malignancy that required active treatment within 6 months of the first dose of treatment
  • History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, such that trial participation is not in the best interest of the subject, including but not limited to uncontrolled hypertension or clinically significant cardiovascular disease, myocardial infarction within the previous 3 months, active infection or pneumonitis or other pulmonary disease requiring systemic therapy, clinically significant gastritis or peptic ulcer disease (that would preclude the use of indomethacin), stroke of other symptoms of cerebral vascular insufficient within the last 3 months, autoimmune disease that has required systemic treatment within the past 2 years (other than hormone replacement doses), or uncontrolled psychiatric or substance abuse disorders.
  • Pregnancy or lactation.
  • Known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies), active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02950259

Contacts
Contact: David Page, MD 503-215-5696 David.Page2@providence.org
Contact: Nicole Moxon, RN 503-215-2619 Nicole.Moxon@providence.org

Locations
United States, Oregon
Providence Portland Medical Center Recruiting
Portland, Oregon, United States, 97213
Contact: David Page, MD    503-215-5696    David.Page2@Providence.org   
Contact: Nicole Moxon, RN    503-215-2619    nicole.moxon@providence.org   
Sub-Investigator: Alison Conlin, MD         
Sub-Investigator: Todd Crocenzi, MD         
Sub-Investigator: Brendan Curti, MD         
Principal Investigator: John Godwin, MD         
Sub-Investigator: Rom Leidner, MD         
Sub-Investigator: Rui Li, MD, PhD         
Sub-Investigator: Rachel Sanborn, MD         
Sub-Investigator: Walter Urba, MD, PhD         
Sponsors and Collaborators
Providence Health & Services
IRX Therapeutics
Investigators
Principal Investigator: David Page, MD Providence Health & Services
  More Information

Additional Information:
Responsible Party: Providence Health & Services
ClinicalTrials.gov Identifier: NCT02950259     History of Changes
Other Study ID Numbers: 16-126B
IRX-2 2016-B ( Other Identifier: IRX Therapeutics )
Study First Received: October 28, 2016
Last Updated: March 1, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Providence Health & Services has agreed to allow IRX Therapeutics to have access PHI for auditing purposes. Any non-Providence Health & Services employee who will access PHI will be required to sign a confidentiality agreement and will not be permitted to remove PHI from Providence Health & Services.

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Providence Health & Services:
Breast Cancer
Early Stage Breast Cancer
Male breast cancer
IRX-2
Immunotherapy

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms
Breast Neoplasms, Male
Neoplasms by Site
Breast Diseases
Skin Diseases
Cyclophosphamide
Indomethacin
Omeprazole
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Anti-Ulcer Agents
Gastrointestinal Agents
Proton Pump Inhibitors
Enzyme Inhibitors
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Anti-Inflammatory Agents
Gout Suppressants
Tocolytic Agents

ClinicalTrials.gov processed this record on August 22, 2017